Monika Casanova joining PolyPeptide as CHRO and member of the PMC
9 May 2022 - Baar, 9 May 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide development and manufacturing, today announced that Monika Casanova has joined the Group […]
Read morePolyPeptide announces results of the annual General Meeting 2022
26 Apr 2022 - Zug, 26 April 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide development and manufacturing, today announced that the shareholders approved all proposals put […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2022
1 Apr 2022 - Zug, 1 April 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide custom development and manufacturing, published today the invitation to its first annual […]
Read morePolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients
1 Sep 2021 - Long-term collaborative development process for peptide API successfully completed and continued with commercial supply agreement Zug, 1 September 2021 – PolyPeptide is pleased to announce that […]
Read morePolyPeptide Group appoints Raymond De Vré as new Chief Executive Officer
16 Feb 2021 - Feb 16, 2021 7:00 AM PolyPeptide Group, a global leader in peptide manufacturing and development, today announced the appointment of Dr. Raymond De Vré as its […]
Read morePolyPeptide Group Selected by Novavax to Manufacture Critical Intermediates of Matrix-M™ Adjuvant for its COVID-19 Vaccine
4 Jun 2020 - The PolyPeptide Group, a global Contract Development and Manufacturing Organization (CDMO) for Peptide, Peptidomimetic and other Drug Substances, has announced that it has partnered with Novavax […]
Read more